---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-101773"
form_type: "8-K"
ticker: "REPL"
cik: "0001737953"
company_name: "Replimune Group, Inc."
filed_at: "2023-09-19T23:59:59+00:00"
generated_at: "2026-06-10T13:37:25.890290+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Replimune names Emily Hill as CFO; previously CFO of PTC Therapeutics

## Summary
- Appointed Emily Hill as CFO effective Sept 18, 2023; she was previously CFO of PTC Therapeutics.
- Base salary $495,000, target bonus 40%, plus 125,000 stock options at $18.00 and 83,330 RSUs, vesting over 4 years.
- Termination benefits: 12 months salary plus COBRA; enhanced upon change of control.
- Ms. Hill brings 15+ years biotech experience, including roles at PTC, Warner Chilcott, and Genzyme.

## SEC filing metadata
- accession: 0001104659-23-101773
- form_type: 8-K
- ticker: REPL
- cik: 0001737953
- company_name: Replimune Group, Inc.
- filed_at: 2023-09-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737953/000110465923101773/0001104659-23-101773-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737953/000110465923101773/tm2326363d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-101773
- JSON: https://secwatch.observer/filing/0001104659-23-101773.json
- Plain text: https://secwatch.observer/filing/0001104659-23-101773.txt

## Key facts
- Executive change
  Emily Hill was appointed as Chief Financial Officer at Replimune Group, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On September 19, 2023, Replimune Group, Inc. (“Replimune”) announced the appointment of Emily Hill as its Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737953/000110465923101773/0001104659-23-101773-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.